CPA
MRVI icon

Capital Performance Advisors’s Maravai LifeSciences MRVI Stock Holding History

Capital Performance Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-141
Closed -$1.17K – 1708
2024
Q3 		$1.17K Buy
+141
New +$1.22K ﹤0.01% 1827

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Performance Advisors's MRVI Position: Q4 2024 in Review

Capital Performance Advisors sold out of Maravai LifeSciences (MRVI) in Q4 2024, closing a stake of 141 shares — an estimated $1.17K sold.

Capital Performance Advisors first reported a position in MRVI in Q3 2024 and held it in 1 quarter. The position peaked at $1.17K in Q3 2024. 185 funds tracked by Wall St. Rank hold MRVI as of Q4 2024.

  • Capital Performance Advisors reported no remaining Maravai LifeSciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 141 Maravai LifeSciences shares in Q4 2024, an estimated $1.17K.
  • Capital Performance Advisors first reported a position in Maravai LifeSciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Maravai LifeSciences position peaked at $1.17K in Q3 2024.
  • 185 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.